Please assess the completion status of the following clinical trial:

Trial Title: Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- Patients with relapsed, advanced and/or metastatic cancer who have failed available standard treatments or who are not candidates for standard therapy.~Patients must have measurable disease~* Age ≥ 18 years.~* Acceptable renal function~* Acceptable liver function~* Acceptable hematological status (without hematologic support~* Acceptable coagulation status~* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~* Life expectancy of at least three months.~* A negative serum pregnancy test (if female and aged between 18-55 years old).~* Women who are pregnant or breast feeding are not to be included.~* Patients, both females and males, of reproductive potential must agree to use adequate contraception during and for six months after the last infusion of HuMax-TF-ADC.~* Following receipt of verbal and written information about the study, patients must provide signed informed consent before any study-related activity is carried out.~Exclusion Criteria:~* Known past or current coagulation defects.~* Ongoing major bleeding,~* Have clinically significant cardiac disease~* A baseline QT interval as corrected by Fridericia's formula (QTcF) \> 450 msec, a complete left bundle branch block (defined as a QRS interval ≥ 120 msec in left bundle branch block form) or an incomplete left bundle branch block.~* Have received granulocyte colony stimulating factor (G-CSF) or granulocyte/macrophage colony stimulating factor support within one week or pegylated G-CSF within two weeks before the Screening Visit.~* Have received a cumulative dose of corticosteroid ≥ 100 mg (prednisone or equivalent doses of corticosteroids) within two weeks before the first infusion.~* Major surgery within six weeks or open biopsy within 14 days before drug infusion.~* Plan for any major surgery during treatment period.~* Any history of intracerebral arteriovenous malformation, cerebral aneurysm, brain metastases or stroke.~* Any anticancer therapy including; small molecules, immunotherapy, chemotherapy monoclonal antibodies or any other experimental drug within four weeks or five half lives, whichever is longest, before first infusion.~* Prior treatment with bevacizumab within twelve weeks before the first infusion.~* Radiotherapy within 28 days prior to first dose.~* Patients who have not recovered from symptomatic side effects of radiotherapy at the time of initiation of screening procedure.~* Known past or current malignancy other than inclusion diagnosis, except for:~* Cervical carcinoma of Stage 1B or less.~* Non-invasive basal cell or squamous cell skin carcinoma.~* Non-invasive, superficial bladder cancer.~* Prostate cancer with a current PSA level \< 0.1 ng/mL.~* Any curable cancer with a complete response (CR) of \> 5 years duration.~* Known human immunodeficiency virus seropositivity.~* Positive serology (unless due to vaccination or passive immunization due to Ig therapy) for hepatitis B~* Positive serology for hepatitis C based on test at screening.~* Inflammatory bowel disease including Crohn's disease and colitis ulcerosa.~* Inflammatory lung disease including moderate and severe asthma and chronic obstructive pulmonary disease (COPD) requiring chronic medical therapy.~* Ongoing acute or chronic inflammatory skin disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tisotumab Vedotin (HuMax-TF-ADC) (Type: EXPERIMENTAL): All arms of the trial (borh in escalation and expansion phase) will be administered tisotumab vedotin (HuMax-TF-ADC)

Based on this trial design, predict the completion outcome and termination type (if applicable).